Skip to content

Pharminent

Primary Menu
  • Home
    • Pro Hub
Light/Dark Button
Hub
  • Home
  • Clinical Data
  • AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data
  • Clinical Data

AAN 2026: J&J, Kyverna, Capricor and Praxis showcase practice-changing data

BioSpace

This year's American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.

Clinical DataNeuroscienceRead full story

pharminent April 23, 2026 (Last updated: April 23, 2026)

BioSpace

This year’s American Academy of Neurology meeting included a presentation that could one day set a new treatment standard for myasthenia gravis.

Clinical DataNeuroscienceRead full story

Post navigation

Previous: Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care
Next: Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’

Related Stories

  • Clinical Data

Novartis hit as Lp(a) drug fails cardio outcomes trial

pharminent September 7, 2026
  • Clinical Data

Major trial of Roche Alzheimer’s drug kicks off in Europe

pharminent September 7, 2026
  • Clinical Data

AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study

pharminent September 4, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.